Monoclonal Antibodies & Cell Culture
Monoclonal Antibodies & Cell Culture
Cell culture manufacturing is a biotechnological production process that predominantly involves the growth of mammalian cells under controlled, aseptic conditions to produce biological products, including, vaccines (1796- smallpox), enzymes (since 1890s), proteins (insulin manufactured since 1982), and monoclonal antibodies (mAbs; first approved 1986). At the heart of the biotechnology revolution is recombinant DNA technology. Through the genetic modification of host cells, a wide range of biopharmaceutical products can be produced via controlled cell growth and protein expression from engineered cell lines.
Mammalian cell lines, most commonly Chinese hamster ovary (CHO) cells, and in some cases HEK‑293 cells, are the primary hosts for monoclonal antibody production. mAbs emerged following the invention of hybridoma technology in 1975 and are recombinant proteins that bind specific antigens on cancer cells, virus‑infected cells, or bacteria. Beyond natural antibody functions, mAbs are often engineered to exert targeted therapeutic effects, such as neutralizing ligands, blocking receptors, delivering toxins or radioisotopes, binding soluble cytokines, or engaging immune cells through bispecific formats or modified Fc regions.
Clinically, mAbs inhibit abnormal cell growth, mark diseased cells for immune‑mediated destruction, prevent pathogen infection, and treat autoimmune, inflammatory, metabolic, cardiovascular, and neurodegenerative diseases.
Key Issues
mAb production demands high CHO cell titers, intensified seed trains, and robust sterility management. Variability in cell growth and cell cycle progression, mixing, shear and oxygen transfer, media composition and nutrient control, and waste metabolite buildup can significantly impact titer and yield. Genetically stable cell‑line engineering is required to achieve high titers while mitigating chain mispairing and abnormal post‑translational modification risks, particularly for newer modalities such as bispecific antibodies and fusion proteins. Downstream processing bottlenecks include resin costs, large buffer volumes, and the development of high‑concentration formulations.
Process intensification approaches — including high‑cell‑density fed‑batch, perfusion, continuous capture chromatography, single‑pass tangential flow filtration, and integrated continuous processing — introduce challenges related to control strategy, residence‑time distribution, validation, automation, and regulatory filings. As mAbs increasingly target high‑value and personalized therapies, process flexibility, speed‑to‑market, and lifecycle maintainability have become essential design drivers.
How Fluor Helps
Fluor brings more than 40 years of experience in project planning, estimating, feasibility and conceptual studies, basic and detailed engineering, construction, commissioning and qualification of regulatory‑compliant of mammalian cell culture facilities across the North and South America, Europe, and Asia.
Building on its experience with legacy stainless steel, hybrid, and fully single‑use facilities, Fluor delivers modern manufacturing solutions with modular, expansion‑ready spaces that enable evolving production strategies, future capacity expansion, and rapid technology adoption—while maintaining long‑term operational reliability and regulatory confidence.
Process Features
Mammalian cell culture processes are built around controlled scale-up from cell banks through seed trains into production bioreactors, typically operated in fed-batch or perfusion modes. Processes integrate defined media preparation, sterile transfers, and tight control of critical parameters such as pH, temperature, and dissolved oxygen. Downstream operations include clarification, multi-step chromatography (often Protein A capture), viral inactivation and filtration, and ultrafiltration/diafiltration for concentration and buffer exchange.
By the 2010s, advances in cell line development and process intensification increased CHO titers from <1 g/L to >3–5 g/L, enabling a transition from stainless steel to single‑use systems for seed trains and media and buffer preparation. These approaches evolved into today’s platforms, which support fully single‑use upstream processing at 2–6 kL scales, including disposable seed trains, depth filtration and TFF, and hybrid chromatography skids.
Facility Features
mAb facilities are designed as fully integrated, cGMP-compliant environments that support aseptic processing, biosafety containment, and efficient material and personnel flow. Key features include classified cleanrooms, segregated pre- and post-viral spaces, hygienic piping, and high-purity clean utilities such as water for injection and clean steam. HVAC systems provide precise pressure cascades and particulate control, while layouts minimize open processing and maintenance in classified areas. Single‑use facilities can be built in 12 to 24 months and offer lower capital expenditure, easier multiproduct operation, reduced cross‑contamination risk, and elimination of clean in place/sterilize in place. Stainless steel facilities, which require several years and high capital expenditure to build, clean, and validate and operate under campaign-based production constraints, are still used for very high‑volume products requiring 10–25 kL bioreactors and for legacy blockbuster molecules.
Fluor Projects
Continuous Manufacturing Process
Location: California, USA
Scope: Engineering
Fluor provided conceptual, basic, and detailed design for capacity expansion of a mammalian cell culture suite.
Pfizer Monoclonal Antibody Large-Scale Facility (MABs LSF)
Location: Shanbally, Ireland
Scope: Engineering
Fluor provided a conceptual study, overall project master planning, an enhanced post concept design, early preliminary engineering, and established preliminary systems boundaries and constructability reviews. Fluor prepared the support documentation for environmental impact statement and the planning application. The LSF comprises a Large-Scale Manufacturing (LSM) building, warehouse, central utilities building (CUB), administration/laboratories building, secondary wastewater treatment facility and structured parking. LSM includes cell culture, purification, and process support functions to produce mammalian cell culture derived monoclonal antibodies (MAbs).
Large-Scale Cell Culture (LSCC) Facility
Location: Devens, Massachusetts, USA
Scope: Engineering, Procurement, Commission & Qualification
Fluor provided all phases of design and procurement. This greenfield 340,000-square-foot project is designed for commercial biotech manufacturing. Upstream capacity is provided by six 20,000-litre, working-volume commercial bioreactors, supported by three seed trains. One large-scale purification train is provided. Support buildings include cafeteria, laboratory/administration complex, warehouse, and central utilities building. The Lab/Office at the client is certified Gold by LEED, and the manufacturing building and Silver certification. This facility will further enhance the client's ability to meet market demand for a rheumatoid arthritis treatment drug.
Large-Scale Bulk Monoclonal Antibody/Cell Culture Manufacturing Facility
Location: California, USA
Scope: Engineering
Fluor provided conceptual and preliminary design for the first phase of this new 60-acre drug-manufacturing campus. The facility is a multiproduct cGMP manufacturing facility designed to manufacture and purify mammalian cell culture-derived proteins. The project consists of three buildings: Manufacturing Operations Building (NIMO I), lab/office building, and warehouse.
Business Inquiries
Contact Fluor's sales team to learn how Fluor can help you with your business needs and what solutions Fluor offers in your industry. See the buttons below for questions on other topics.